Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemtuzumab ozogamicin - Pfizer

Drug Profile

Gemtuzumab ozogamicin - Pfizer

Alternative Names: Anti-CD33-monoclonal-antibody-calicheamicin; Anti-CD33-monoclonal-antibody-p67-6-calicheamicin-conjugate; CDP-771; CMA-676; Gemtuzumab; HP67-6-N-acetyl-gamma-dimethyl-acbut; Human-anti-CD33-monoclonal-antibody-P67-6-calicheamicin-conjugate; Mylotarg; WAY-CMA-676

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Developer National Cancer Institute (USA); Pfizer
  • Class Aminoglycosides; Cytostatic antibiotics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA damage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 19 Nov 2019 Gruppo Italiano Malattie EMatologiche dell'Adulto plans a phase III trial for Acute myeloid leukemia (Combination therapy, First-line therapy) in USA (IV) in February 2020 (NCT04168502)
  • 07 Oct 2019 Gemtuzumab ozogamicin is not yet available for Acute myeloid leukaemia in Brazil, Chile, Colombia, Cyprus, European Union, Iceland, India, Liechtenstein, Mexico, South Africa, South Korea, Thailand (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top